Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Jesse Schulman who wrote (989)	2/8/2000 3:29:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1386

ITSS: I'm wondering if others are as confused as I am about recent events. The Chairman was quoted by Reuters yesterday in a piece about Pars applying for Easdaq as saying he is not raising fresh funds. I'm wondering if the Chairman knows the company sold 1 Million shares last week at a deep discount. Also, the article attributed the following to the Chairman 'during the phase 2 trial, patients treated with Dexanabinol achieved higher recovery rates than those treated with placebo'. Since there has been no PR on either of these topics, it's not clear why the Chairman is roaming around talking about them. It looks like the IR is out of the loop as is the company doing our PR. Do others on the thread have the same level of confusion as I do? Arnie